3 completed, 1 not yet recruiting. 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Drug Administration Routes: new trials by email Literature Review of Drug Administration Routes trials Research Report on Drug Administration Routes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients BPR-101 capsules:Investigational product for the treatment of BV, Placebo：matching the investigational product in appearance, dosage form, and route of administration - Bacterial Vaginosis | Phase 2 | Not yet recruiting | Chengdu Syncor Pharmaceutical Co., Ltd. | 80 | 2026-04-15 | 2026-03-19 |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US Encorafenib, Binimetinib, Vemurafenib - Melanoma | Completed | Pfizer | 716 | 2022-01-17 | 2025-03-06 | |
| Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Large Esophageal Carcinoma Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration), Triamcinolone Acetonide (route of administration), Prednisone (route of administration) - Esophageal Stenosis Acquired | Not applicable | Completed | Peking University Third Hospital | 66 | 2017-02-10 | 2021-01-20 |
| Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin Lixisenatide (AVE0010), Self-injector pen device (OptiClik®), Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Sanofi | 451 | 2012-02-01 | 2016-10-14 |
Diabetes Mellitus, Type 2 (1) · Melanoma (1) · Vaginosis, Bacterial (1)
Chengdu Syncor Pharmaceutical Co., Ltd. (1) · Peking University Third Hospital (1) · Pfizer (1) · Sanofi (1)
China (2) · United States (2) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Poland (1) · Romania (1) · Russia (1) · Spain (1) · Ukraine (1)
FengXia Xue, Doctor of Medicine(M.D.) (1) · Yonghui Huang, archiater (1)
PMID 18704454, PMID 19302207, PMID 19430800, PMID 19565442, PMID 21296855, PMID 21492854, PMID 22136782, PMID 22638783, PMID 22930171, PMID 24512802, PMID 24830402, PMID 25012990, PMID 25031273